drugset / Trial / NCT01345929

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

NCT01345929

Phase 3 Completed 558 enrolled Merck & Co., Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA 201 IV infusions (1500 mg q8h) versus levofloxacin IV infusions (750 mg qd) for the treatment of adults with a cUTI (including pyelonephritis).

Timeline

Start
2011-06-20
Primary completion
2013-08-11
Completion
2013-09-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CXA-201 Unknown 1500 mg Intravenous
Comparator Levofloxacin Small molecule 750 mg Intravenous

Indications